- Home
- IVZ vs CAI Comparison
IVZ vs CAI Comparison
Compare IVZ & CAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- CAI
- Stock Information
- Founded
- IVZ 1935
- CAI 2008
- Country
- IVZ United States
- CAI United States
- Employees
- IVZ N/A
- CAI N/A
- Industry
- IVZ Investment Managers
- CAI Medical Specialities
- Sector
- IVZ Finance
- CAI Health Care
- Exchange
- IVZ Nasdaq
- CAI Nasdaq
- Market Cap
- IVZ 9.9B
- CAI 9.4B
- IPO Year
- IVZ 1995
- CAI 2025
- Fundamental
- Price
- IVZ $22.59
- CAI $32.85
- Analyst Decision
- IVZ Hold
- CAI Strong Buy
- Analyst Count
- IVZ 16
- CAI 6
- Target Price
- IVZ $19.36
- CAI $35.50
- AVG Volume (30 Days)
- IVZ 4.0M
- CAI 557.8K
- Earning Date
- IVZ 10-21-2025
- CAI 11-12-2025
- Dividend Yield
- IVZ 3.73%
- CAI N/A
- EPS Growth
- IVZ N/A
- CAI N/A
- EPS
- IVZ 0.93
- CAI N/A
- Revenue
- IVZ $6,153,100,000.00
- CAI $533,847,000.00
- Revenue This Year
- IVZ N/A
- CAI $64.66
- Revenue Next Year
- IVZ $9.86
- CAI $45.81
- P/E Ratio
- IVZ $24.21
- CAI N/A
- Revenue Growth
- IVZ 5.83
- CAI 106.53
- 52 Week Low
- IVZ $11.60
- CAI $25.40
- 52 Week High
- IVZ $22.78
- CAI $42.50
- Technical
- Relative Strength Index (RSI)
- IVZ 65.06
- CAI N/A
- Support Level
- IVZ $21.89
- CAI N/A
- Resistance Level
- IVZ $22.73
- CAI N/A
- Average True Range (ATR)
- IVZ 0.46
- CAI 0.00
- MACD
- IVZ -0.04
- CAI 0.00
- Stochastic Oscillator
- IVZ 85.71
- CAI 0.00
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (68% of managed assets) and institutional (32%) clients. At the end of July 2025, the firm had $2.025 trillion in assets under management spread among its equity (60% of AUM), balanced (3%), fixed-income (21%), alternative investment (6%), and money market (10%) operations. Passive products account for 46% of Invesco's total AUM. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.